Immune checkpoint blockade (ICB)-based immunotherapeutic targeting cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death 1 (PD1) signaling have considerably improved ccRCC treatment. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.